Pluristem Therapeutics (PSTI) Reports Clearance in Germany to Initiate Phase III Trial of PLX-PAD Cells in CLI
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced that Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), has cleared Pluristem ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
